175 related articles for article (PubMed ID: 32727929)
1. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carroll MR; Ramalingam P; Salvo G; Fujimoto J; Solis Soto LM; Phoolcharoen N; Hillman RT; Cardnell R; Byers L; Frumovitz M
Int J Gynecol Cancer; 2020 Sep; 30(9):1303-1307. PubMed ID: 32727929
[TBL] [Abstract][Full Text] [Related]
2. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
[TBL] [Abstract][Full Text] [Related]
5. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
7. P63 expression in lung carcinoma: a tissue microarray study of 408 cases.
Au NH; Gown AM; Cheang M; Huntsman D; Yorida E; Elliott WM; Flint J; English J; Gilks CB; Grimes HL
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):240-7. PubMed ID: 15551738
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
9. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
[TBL] [Abstract][Full Text] [Related]
10. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
11. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
12. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Roberts JA; Gonzalez RS; Das S; Berlin J; Shi C
Hum Pathol; 2017 Dec; 70():49-54. PubMed ID: 29037958
[TBL] [Abstract][Full Text] [Related]
13. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
Sharabi A; Kim SS; Kato S; Sanders PD; Patel SP; Sanghvi P; Weihe E; Kurzrock R
Oncologist; 2017 Jun; 22(6):631-637. PubMed ID: 28550027
[TBL] [Abstract][Full Text] [Related]
14. Small cell neuroendocrine carcinomas of the lung do not harbor high-risk human papillomavirus.
Hartley CP; Steinmetz HB; Memoli VA; Tafe LJ
Hum Pathol; 2015 Apr; 46(4):577-82. PubMed ID: 25661244
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63.
McCluggage WG; Kennedy K; Busam KJ
Am J Surg Pathol; 2010 Apr; 34(4):525-32. PubMed ID: 20182342
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
[TBL] [Abstract][Full Text] [Related]
18. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
[TBL] [Abstract][Full Text] [Related]
19. Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity.
Zhang TM; Wang W
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):31-34. PubMed ID: 33287919
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
